Document is current
Any future updates will be listed below
-
Authors
,
Oak, Ninad
Cherniack, Andrew D.
Mashl, R. Jay
Hirsch, Fred R.
Ding, Li
Beroukhim, Rameen
Gümüş, Zeynep H.
Plon, Sharon E.
Huang, Kuan-lin http://orcid.org/0000-0002-5537-5817
-
Funding
Funding for this research was provided by:
National Human Genome Research Institute (U41HG009649, U41HG009649, U41HG009649)
- License Information
-
More Information
Article History
Received: 2 December 2019
Accepted: 7 May 2020
First Online: 29 May 2020
Ethics approval and consent to participate
: The need for Institutional Review Board Approval at our institution (Icahn School of Medicine at Mount Sinai, New York) was waived for this study as all data used from this project had previously been generated as part of The Cancer Genome Atlas Project and none of the results reported in this manuscript can be used to identify individual patients.
: Not applicable.
: S.E.P. is a member of the Baylor Genetics laboratory scientific advisory panel. A.D.C receives research funding from Bayer. R.B. owns equity in Ampressa Therapeutics and receives research funding from Novartis. The remaining authors declare that they have no competing interests.
